Two large randomized controlled studies (ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes]) have studied the use of the combination of an ACE inhibitor with a ARAII.